The effects of pregabalin on sleep disturbance symptoms among individuals with fibromyalgia syndrome Export

@article{citeulike:4614967, abstract = {Sleep disturbances are common in patients with fibromyalgia (FM). The objective of this analysis was to evaluate the effects of pregabalin on sleep in patients with FM. Analyses were based on two randomized, double-blind, placebo-controlled trials of pregabalin (300 mg, 450 mg, and 600 mg daily) in adult FM patients. Sleep outcomes included the Medical Outcomes Study (MOS) Sleep Scale and a daily diary assessment of sleep quality. Treatment effects were evaluated using analysis of covariance. Clinically important differences (CID) in the Sleep Quality Diary and MOS Sleep Disturbance scores were estimated using mixed-effects models of changes in scores as a function of patients' global impressions of change. Mediation modeling was used to quantify the direct treatment effects on sleep in contrast to indirect influence of the treatment on sleep via pain. A total of 748 and 745 patients were randomized in the respective studies. Patients were predominantly Caucasian females, average age 48–50 years, on average had FM for 9–10 years, and experienced moderate to severe baseline pain. Pregabalin significantly improved the Sleep Quality Diary ( P  < 0.001), MOS Sleep Disturbance ( P  < 0.01), MOS Quantity of Sleep ( P  < 0.003), and MOS Sleep Problems Index scores ( P  < 0.02) relative to placebo. Treatment effects for the 450 mg and 600 mg groups exceeded the estimated CID thresholds of 0.83 and 7.9 for the Sleep Quality Diary and MOS Sleep Disturbance scores, respectively. Mediation models indicated that 43–80\% of the benefits on sleep (versus placebo) were direct effects of pregabalin, with the remainder resulting from an indirect effect of treatment via pain relief. These data demonstrate improvement in FM-related sleep dysfunction with pregabalin therapy. The majority of this benefit was a direct effect of pregabalin on the patients' insomnia, while the remainder occurred through the drug's analgesic activity.}, author = {Russell, Jon I. and Crofford, Leslie J. and Leon, Teresa and Cappelleri, Joseph C. and Bushmakin, Andrew G. and Whalen, Ed and Barrett, Jeannette A. and Sadosky, Alesia}, citeulike-article-id = {4614967}, citeulike-linkout-0 = {http://dx.doi.org/10.1016/j.sleep.2009.01.009}, citeulike-linkout-1 = {http://linkinghub.elsevier.com/retrieve/pii/S1389945709000586}, citeulike-linkout-2 = {http://view.ncbi.nlm.nih.gov/pubmed/19410509}, citeulike-linkout-3 = {http://www.hubmed.org/display.cgi?uids=19410509}, doi = {10.1016/j.sleep.2009.01.009}, issn = {13899457}, journal = {Sleep Medicine}, keywords = {fibromyalgia, insomnia, pregabalin}, month = {June}, number = {6}, pages = {604--610}, posted-at = {2009-05-27 12:02:20}, priority = {3}, title = {The effects of pregabalin on sleep disturbance symptoms among individuals with fibromyalgia syndrome}, url = {http://dx.doi.org/10.1016/j.sleep.2009.01.009}, volume = {10}, year = {2009} }

TY - JOUR ID - citeulike:4614967 L3 - citeulike-article-id:4614967 N2 - Sleep disturbances are common in patients with fibromyalgia (FM). The objective of this analysis was to evaluate the effects of pregabalin on sleep in patients with FM. Analyses were based on two randomized, double-blind, placebo-controlled trials of pregabalin (300 mg, 450 mg, and 600 mg daily) in adult FM patients. Sleep outcomes included the Medical Outcomes Study (MOS) Sleep Scale and a daily diary assessment of sleep quality. Treatment effects were evaluated using analysis of covariance. Clinically important differences (CID) in the Sleep Quality Diary and MOS Sleep Disturbance scores were estimated using mixed-effects models of changes in scores as a function of patients’ global impressions of change. Mediation modeling was used to quantify the direct treatment effects on sleep in contrast to indirect influence of the treatment on sleep via pain. A total of 748 and 745 patients were randomized in the respective studies. Patients were predominantly Caucasian females, average age 48–50 years, on average had FM for 9–10 years, and experienced moderate to severe baseline pain. Pregabalin significantly improved the Sleep Quality Diary ( P  < 0.001), MOS Sleep Disturbance ( P  < 0.01), MOS Quantity of Sleep ( P  < 0.003), and MOS Sleep Problems Index scores ( P  < 0.02) relative to placebo. Treatment effects for the 450 mg and 600 mg groups exceeded the estimated CID thresholds of 0.83 and 7.9 for the Sleep Quality Diary and MOS Sleep Disturbance scores, respectively. Mediation models indicated that 43–80% of the benefits on sleep (versus placebo) were direct effects of pregabalin, with the remainder resulting from an indirect effect of treatment via pain relief. These data demonstrate improvement in FM-related sleep dysfunction with pregabalin therapy. The majority of this benefit was a direct effect of pregabalin on the patients’ insomnia, while the remainder occurred through the drug’s analgesic activity. IS - 6 JF - Sleep Medicine SN - 13899457 EP - 610 TI - The effects of pregabalin on sleep disturbance symptoms among individuals with fibromyalgia syndrome VL - 10 SP - 604 KW - fibromyalgia KW - insomnia KW - pregabalin AU - Russell, Jon AU - Crofford, Leslie AU - Leon, Teresa AU - Cappelleri, Joseph AU - Bushmakin, Andrew AU - Whalen, Ed AU - Barrett, Jeannette AU - Sadosky, Alesia PY - 2009/06// UR - http://dx.doi.org/10.1016/j.sleep.2009.01.009 ER -